

## PRESS RELEASE

---

### **ProBioGen Signs next GlymaxX<sup>®</sup> ADCC Technology Deal with TOP 10 Pharma Company for Therapeutic Antibody Platform**

*Berlin, Germany, February 20th, 2013* - Another global pharma company has licensed ProBioGen's GlymaxX<sup>®</sup> ADCC-enhancement technology. The license covers the modification of the pharma's antibody production platform for the generation of antibodies with enhanced potency. The continued licensing success demonstrates the industry's endorsement of GlymaxX<sup>®</sup>. The GlymaxX<sup>®</sup> technology is highly versatile since it can be applied to any starter or production cell line. It allows both, the robust permanent modification of established antibody expression platforms, as well as the rapid conversion of existing antibody producer clones to produce ADCC-enhanced molecules.

The GlymaxX<sup>®</sup> technology is based on the stable expression of a heterologous enzyme in the antibody producing cells. GlymaxX<sup>®</sup> prevents antibody fucosylation almost completely, but moreover allows the exact adjustment of any desired fucosylation level through the controlled addition of fucose into the culture medium.

The license with an option for a commercial license covers the modification of the company's antibody production platform and the generation of multiple antibodies with enhanced ADCC potency. Financial details are not disclosed.

The technology can be licensed royalty-free, based on milestone-dependent license fees only.

-----

#### **About ProBioGen - [www.probiogen.de](http://www.probiogen.de)**

ProBioGen is an internationally operating technology provider and Contract Development and Manufacturing Organization (CDMO) with almost 20 years of experience in cell culture, process development, and GMP-manufacturing. ProBioGen is a competent and reliable CDMO partner, offering customized solutions for even the most challenging development and manufacturing requirements. This is backed by the company's established, fee-for-service-based CHO cell and media platform, and its innovative platform technologies, as well as the comprehensive portfolio of cell-based activity assays. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).

ProBioGen was founded 1994 and is located in Berlin, Germany.

#### **About GlymaxX<sup>®</sup> - [www.glymaxx.de](http://www.glymaxx.de)**

The GlymaxX<sup>®</sup> technology, developed by ProBioGen, prevents the addition of the sugar "fucose" to the N-linked antibody carbohydrate part by antibody producing cells. The absence of fucose is known to greatly enhance ADCC. The GlymaxX<sup>®</sup> technology is based on the introduction of a gene for an enzyme which deflects the producer cells' pathway of fucose biosynthesis. GlymaxX<sup>®</sup> is universally applicable to different CHO hosts and other eukaryotic cell species, and it is simple and potent. GlymaxX<sup>®</sup> can be rapidly applied in a few weeks to any existing antibody producer cell line, or can be introduced into entire animal cell expression platforms by modifying host cell lines.

ProBioGen offers this technology royalty-free as service or as license to third parties.

**Contact ProBioGen**

*Dr. Gabriele Schneider  
Vice President Business Development  
ProBioGen AG  
Goethestrasse 54  
13086 Berlin  
Germany  
Phone: +49 (0)30 924 006-0  
Email: [cmo@probiogen.de](mailto:cmo@probiogen.de)*

*More information:  
[www.probiogen.de](http://www.probiogen.de)  
[www.glymaxx.de](http://www.glymaxx.de)*